Affimed Announces Proposed Public Offering of Common Shares
January 12 2021 - 4:01PM
Heidelberg, Germany, January 12, 2021 – Affimed
N.V. (“Affimed” or the “Company”) (Nasdaq: AFMD), a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer, today announced that it has
commenced an underwritten public offering of its common shares. The
Company expects to grant the underwriters a 30-day over-allotment
option to purchase up to 15 percent of the number of common shares
sold in connection with the offering. All of the shares in the
offering will be sold by Affimed. This offering is subject to
market conditions and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Jefferies LLC, SVB Leerink LLC and Credit Suisse
Securities (USA) LLC are acting as joint book-running managers of
the offering. A shelf registration statement relating to these
securities filed with the Securities and Exchange Commission (the
“SEC”) was declared effective by the SEC on December 30, 2020. The
offering will be made only by means of a prospectus and prospectus
supplement. A preliminary prospectus supplement and accompanying
prospectus related to the offering have been filed with the SEC and
are available at the SEC’s website located at www.sec.gov. Copies
of the preliminary prospectus supplement and accompanying
prospectus related to the offering may be obtained by contacting
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone
at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com, SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, or by telephone at (800) 808-7525 ext. 6132 or by email at
syndicate@svbleerink.com, or Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, NC 27560, or by telephone at (800)-221-1037, or by
email at usa.prospectus@credit-suisse.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of, these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage
immuno-oncology company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat hematologic and solid tumors. The
Company is currently enrolling patients into a
registration-directed study of AFM13 for CD30-positive
relapsed/refractory peripheral T cell lymphoma and into a Phase
1/2a dose escalation/expansion study of AFM24 for the treatment of
advanced EGFR-expressing solid tumors.
Forward-looking Statements
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the proposed offering of common shares and the anticipated use of
the net proceeds. No assurance can be given that the offering
discussed above will be completed on the terms described, or at
all, or that the net proceeds of the offering will be used as
indicated. Forward-looking statements are subject to numerous
conditions, many of which are beyond the control of the company,
including those set forth in the Risk Factors section of the
company’s registration statement and preliminary prospectus for the
company’s offering filed with the Securities and Exchange
Commission (“SEC”). Copies are available on the SEC’s website,
www.sec.gov. The company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.forward-looking statements.
Affimed Investor and Media Contact:Alexander
Fudukidis, Head of Investor RelationsE-Mail:
a.fudukidis@affimed.com, IR@affimed.comTel.: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024